title: Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer.
abstract: BACKGROUND
  Bone metastases are the most critical complication of prostate cancer (PCa), resulting in severe morbidity and mortality. Tumor necrosis factor receptor superfamily member 11b (TNFRSF11B) is a critical regulator between PCa cells and the bone environment. Recently, TNFRSF11B rs10505346 has been implicated in PCa risk in the Cancer Genetic Markers of Susceptibility genomewide association study. However, the association between this variant and biochemical failure in PCa patients receiving radical prostatectomy (RP) has not been determined.
  
  
  METHODS
  Associations of TNFRSF11B rs10505346 with age at diagnosis, preoperative prostate-specific antigen (PSA) level, Gleason score, pathologic stage, surgical margin, and PSA recurrence were evaluated in a cohort of 314 localized PCa patients receiving RP. The prognostic significance on PSA recurrence was assessed by Kaplan-Meier analysis and Cox regression model.
  
  
  RESULTS
  The mean level of preoperative PSA and the relative risks of PSA recurrence after RP were lower in individuals with T allele than in those with the G allele at TNFRSF11B rs10505346 (P = 0.019 and 0.014, respectively). The T allele of rs10505346 remained a protective factor against PSA recurrence (P = 0.022) in multivariate Cox regression model after considering all clinicopathological risk factors except PSA level.
  
  
  CONCLUSIONS
  Our data suggest that TNFRSF11B rs10505346 is associated with PSA level and might be a prognostic factor for the recurrence of PSA in PCa patients receiving RP.
authors.affiliation: Department of Pharmacy, China Medical University, Taichung, Taiwan.
authors.forename: Bo-Ying
authors.initials: BY
authors.lastname: Bao
authors.forename: Victor C
authors.initials: VC
authors.lastname: Lin
authors.forename: Shu-Hung
authors.initials: SH
authors.lastname: Huang
authors.forename: Jiunn-Bey
authors.initials: JB
authors.lastname: Pao
authors.forename: Ta-Yuan
authors.initials: TY
authors.lastname: Chang
authors.forename: Te-Ling
authors.initials: TL
authors.lastname: Lu
authors.forename: Yu-Hsuan
authors.initials: YH
authors.lastname: Lan
authors.forename: Lu-Min
authors.initials: LM
authors.lastname: Chen
authors.forename: Wen-Chien
authors.initials: WC
authors.lastname: Ting
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Yang
authors.forename: Chi-Jeng
authors.initials: CJ
authors.lastname: Hsieh
authors.forename: Shu-Pin
authors.initials: SP
authors.lastname: Huang
mesh_terms: D000368:Aged; D000483:Alleles; D014408:Biomarkers, Tumor / Q000235:genetics*; D015331:Cohort Studies; D018450:Disease Progression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009367:Neoplasm Staging; D053244:Osteoprotegerin / Q000235:genetics*; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D016016:Proportional Hazards Models; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000601:surgery*
chemical_list: D014408:Biomarkers, Tumor; D053244:Osteoprotegerin